Development of PF-06671008, a highly potent anti-P-cadherin/anti-CD3 bispecific DART molecule with extended half-life for the treatment of cancer

Antibodies

Volumn 5, Issue 1, 2016, Pages

  Root, Adam R ^a   Cao, Wei ^a   Li, Bilian ^a   LaPan, Peter ^a   Meade, Caryl ^a   Sanford, Jocelyn ^a   Jin, Macy ^a   O’Sullivan, Cliona ^a   Cummins, Emma ^a   Lambert, Matthew ^a   Sheehan, Alfredo D ^a   Ma, Weijun ^a   Gatto, Scott ^a   Kerns, Kelvin ^a   Lam, Khetemenee ^a   D’Antona, Aaron M ^a   Zhu, Lily ^a   Brady, William A ^a   Benard, Susan ^a   King, Amy ^a   He, Tao ^a   Racie, Lisa ^a   Arai, Maya ^a   Barrett, Dianah ^a   Stochaj, Wayne ^a   Lavallie, Edward R ^a   Apgar, James R ^a   Svenson, Kristine ^a   Mosyak, Lidia ^a   Yang, Yinhua ^b   Chichili, Gurunadh R ^b   Liu, Liqin ^b   Li, Hua ^b   Burke, Steve ^b   Johnson, Syd ^b   Alderson, Ralph ^b   Finlay, William J J ^a   Lin, Laura ^a   Olland, Stéphane ^a   Somers, William ^a   Bonvini, Ezio ^b   Gerber, Hans Peter ^a   May, Chad ^a   Moore, Paul A ^b   Tchistiakova, Lioudmila ^a   Bloom, Laird ^a   more..

^a PFIZER INC   (United States)

^b Analytical Sciences   (United States)

Author keywords

Bispecific; Cancer; Immuno oncology; P cadherin; Re targeting; T cell

Indexed keywords

ANTINEOPLASTIC AGENT; CD3 ANTIGEN; DUAL AFFINITY RE TARGETING PROTEIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; P CADHERIN; PF 06671008; PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UVOMORULIN;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CRYSTALLOGRAPHY; CYTOTOXIC T LYMPHOCYTE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG HALF LIFE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE SEQUENCE; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR CLONING; MOUSE; NEOPLASM; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY; SIZE EXCLUSION CHROMATOGRAPHY; SURFACE PLASMON RESONANCE; TUMOR GROWTH;

EID: 84988940645     PISSN: 20734468     EISSN: None     Source Type: Journal    
DOI: 10.3390/antib5010006     Document Type: Article

References (42)

1. Cheung, L.W.; Leung, P.C.; Wong, A.S. Cadherin switching and activation of p120 catenin signaling are mediators of gonadotropin-releasing hormone to promote tumor cell migration and invasion in ovarian cancer. Oncogene 2010, 29, 2427–2440. [CrossRef][PubMed]
2. Paredes, J.; Stove, C.; Stove, V.; Milanezi, F.; van Marck, E.; Derycke, L.; Mareel, M.; Bracke, M.; Schmitt, F.C. P-cadherin is up-regulated by the antiestrogen ICI 182,780 and promotes invasion of human breast cancer cells. Cancer Res. 2004, 64, 8309–8317. [CrossRef][PubMed]
3. Ribeiro, A.S.; Albergaria, A.; Sousa, B.; Correia, A.L.; Bracke, M.; Seruca, R.; Schmitt, F.C.; Paredes, J. Extracellular cleavage and shedding of P-cadherin: A mechanism underlying the invasive behaviour of breast cancer cells. Oncogene 2010, 29, 392–402. [CrossRef][PubMed]
4. Taniuchi, K.; Nakagawa, H.; Hosokawa, M.; Nakamura, T.; Eguchi, H.; Ohigashi, H.; Ishikawa, O.; Katagiri, T.; Nakamura, Y. Overexpressed P-cadherin/CDH3 promotes motility of pancreatic cancer cells by interacting with p120ctn and activating rho-family GTPases. Cancer Res. 2005, 65, 3092–3099. [PubMed]
5. Hardy, R.G.; Tselepis, C.; Hoyland, J.; Wallis, Y.; Pretlow, T.P.; Talbot, I.; Sanders, D.S.A.; Matthews, G.; Morton, D.; Jankowski, J.A.Z. Aberrant P-cadherin expression is an early event in hyperplastic and dysplastic transformation in the colon. Gut 2002, 50, 513–519. [CrossRef][PubMed]
6. Imai, K.; Hirata, S.; Irie, A.; Senju, S.; Ikuta, Y.; Yokomine, K.; Harao, M.; Inoue, M.; Tsunoda, T.; Nakatsuru, S., et al. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers. Clin. Cancer Res. 2008, 14, 6487–6495. [CrossRef][PubMed]
7. Paredes, J.; Albergaria, A.; Oliveira, J.T.; Jeronimo, C.; Milanezi, F.; Schmitt, F.C. P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clin. Cancer Res. 2005, 11, 5869–5877. [CrossRef][PubMed]
8. Stefansson, I.M.; Salvesen, H.B.; Akslen, L.A. Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. J. Clin. Oncol. 2004, 22, 1242–1252. [CrossRef][PubMed]
9. Zimmerman, Z.; Maniar, T.; Nagorsen, D. Unleashing the clinical power of T cells: CD19/CD3 bi-specific T cell engager (BiTE®) antibody construct blinatumomab as a potential therapy. Int. Immunol. 2015, 27, 31–37. [CrossRef][PubMed]
10. Lameris, R.; de Bruin, R.C.; Schneiders, F.L.; van Bergen en Henegouwen, P.M.; Verheul, H.M.; de Gruijl, T.D.; van der Vliet, H.J. Bispecific antibody platforms for cancer immunotherapy. Crit. Rev. Oncol. Hematol. 2014, 92, 153–165. [CrossRef][PubMed]
11. Carter, P.J.; Senter, P.D. Antibody-drug conjugates for cancer therapy. Cancer J. 2008, 14, 154–169. [CrossRef][PubMed]
12. Velders, M.P.; van Rhijn, C.M.; Oskam, E.O.; Fleuren, G.J.; Warnaar, S.O.; Litvinov, S.V. The impact of antigen density and antibody affinity on antibody-dependent cellular cytotoxicity: Relevance for immunotherapy of carcinomas. Br. J. Cancer 1998, 78, 478–483. [CrossRef][PubMed]
13. Smith-Garvin, J.E.; Koretzky, G.A.; Jordan, M.S. T cell activation. Annu. Rev. Immunol. 2009, 27, 591–619. [CrossRef][PubMed]
14. Voskoboinik, I.; Whisstock, J.C.; Trapani, J.A. Perforin and granzymes: Function, dysfunction and human pathology. Nat. Rev. Immunol. 2015, 15, 388–400. [CrossRef][PubMed]
15. Baeuerle, P.A.; Reinhardt, C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 2009, 69, 4941–4944. [CrossRef][PubMed]
16. Johnson, S.; Burke, S.; Huang, L.; Gorlatov, S.; Li, H.; Wang, W.; Zhang, W.; Tuaillon, N.; Rainey, J.; Barat, B., et al. Effector cell recruitment with novel fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion. J. Mol. Biol. 2010, 399, 436–449. [CrossRef][PubMed]
17. Moore, P.A.; Zhang, W.; Rainey, G.J.; Burke, S.; Li, H.; Huang, L.; Gorlatov, S.; Veri, M.C.; Aggarwal, S.; Yang, Y., et al. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood 2011, 117, 4542–4551. [CrossRef][PubMed]
18. Ridgway, J.B.B.; Presta, L.G.; Carter, P. “Knobs-into-holes” engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 1996, 9, 617–621. [CrossRef][PubMed]
19. Atwell, S.; Ridgway, J.B.B.; Wells, J.A.; Carter, P. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J. Mol. Biol. 1997, 270, 26–35. [CrossRef][PubMed]
20. Zhang, C.C.; Yan, Z.; Zhang, Q.; Kuszpit, K.; Zasadny, K.; Qiu, M.; Painter, C.L.; Wong, A.; Kraynov, E.; Arango, M.E., et al. PF-03732010: A fully human monoclonal antibody against P-cadherin with antitumor and antimetastatic activity. Clin. Cancer Res. 2010, 16, 5177–5188. [CrossRef][PubMed]
21. Yoshioka, H.; Yamamoto, S.; Hanaoka, H.; Iida, Y.; Paudyal, P.; Higuchi, T.; Tominaga, H.; Oriuchi, N.; Nakagawa, H.; Shiba, Y., et al. In vivo therapeutic effect of CDH3/P-cadherin-targeting radioimmunotherapy. Cancer Immunol. Immunother. 2012, 61, 1211–1220. [CrossRef][PubMed]
22. Suzuki, S.; Sano, K.; Tanihara, H. Diversity of the cadherin family: Evidence for eight new cadherins in nervous tissue. Cell Regul. 1991, 2, 261–270. [CrossRef][PubMed]
23. Fennell, B.J.; McDonnell, B.; Tam, A.S.; Chang, L.; Steven, J.; Broadbent, I.D.; Gao, H.; Kieras, E.; Alley, J.; Luxenberg, D., et al. CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery. MAbs 2013, 5, 882–895. [CrossRef][PubMed]
24. Bluemel, C.; Hausmann, S.; Fluhr, P.; Sriskandarajah, M.; Stallcup, W.B.; Baeuerle, P.A.; Kufer, P. Epitope distance to the target cell membrane and antigen size determine the potency of t cell-mediated lysis by bite antibodies specific for a large melanoma surface antigen. Cancer Immunol. Immunother. 2010, 59, 1197–1209. [CrossRef][PubMed]
25. Perisic, O.; Webb, P.A.; Holliger, P.; Winter, G.; Williams, R.L. Crystal structure of a diabody, a bivalent antibody fragment. Structure 1994, 2, 1217–1226. [CrossRef]
26. Carmichael, J.A.; Power, B.E.; Garrett, T.P.J.; Yazaki, P.J.; Shively, J.E.; Raubischek, A.A.; Wu, A.M.; Hudson, P.J. The crystal structure of an anti-CEA scFv diabody assembled from t84.66 scFvs in VL-to-VH orientation: Implications for diabody flexibility. J. Mol. Biol. 2003, 326, 341–351. [CrossRef]
27. Roopenian, D.C.; Akilesh, S. FcRn: The neonatal Fc receptor comes of age. Nat. Rev. Immunol. 2007, 7, 715–725. [CrossRef][PubMed]
28. Kasaian, M.T.; Raible, D.; Marquette, K.; Cook, T.A.; Zhou, S.; Tan, X.Y.; Tchistiakova, L. IL-13 antibodies influence IL-13 clearance in humans by modulating scavenger activity of IL-13R2. J. Immunol. 2011, 187, 561–569. [CrossRef][PubMed]
29. Shapiro, L.; Weis, W.I. Structure and biochemistry of cadherins and catenins. Cold Spring Harb. Perspect. Biol. 2009, 1. [CrossRef][PubMed]
30. Boggon, T.J.; Murray, J.; Chappuis-Flament, S.; Wong, E.; Gumbiner, B.M.; Shapiro, L. C-cadherin ectodomain structure and implications for cell adhesion mechanisms. Science 2002, 296, 1308–1313. [CrossRef][PubMed]
31. Holliger, P.; Prospero, T.; Winter, G. “Diabodies”: Small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. USA 1993, 90, 6444–6448. [CrossRef][PubMed]
32. Li, L.; Olafsen, T.; Anderson, A.; Wu, A.M.; Raubitschek, A.A.; Shively, J.E. Reduction of kidney uptake in radiometal labeled peptide linkers conjugated to recombinant antibody fragments. Site-specific conjugation of DOTA-peptides to a cys-diabody. Bioconjug. Chem. 2002, 13, 985–995. [CrossRef][PubMed]
33. Olafsen, T.; Cheung, C.; Yazaki, P.J.; Li, L.; Sundaresan, G.; Gambhir, S.S.; Sherman, M.A.; Williams, L.E.; Shively, J.E.; Raubitschek, A.A., et al. Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications. Protein Eng. Des. Sel. 2004, 17, 21–27. [CrossRef][PubMed]
34. Muller, D.; Karle, A.; Meissburger, B.; Hofig, I.; Stork, R.; Kontermann, R.E. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J. Biol. Chem. 2007, 282, 12650–12660. [CrossRef][PubMed]
35. Stork, R.; Campigna, E.; Robert, B.; Muller, D.; Kontermann, R.E. Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives. J. Biol. Chem. 2009, 284, 25612–25619. [CrossRef][PubMed]
36. Zugmaier, G.; Klinger, M.; Schmidt, M.; Subklewe, M. Clinical overview of anti-CD19 BiTE® and ex vivo data from anti-CD33 BiTE® as examples for retargeting T cells in hematologic malignancies. Mol. Immunol. 2015, 67, 58–66. [CrossRef][PubMed]
37. Carter, P.J. Introduction to current and future protein therapeutics: A protein engineering perspective. Exp. Cell Res. 2011, 317, 1261–1269. [CrossRef][PubMed]
38. Kranz, D.M.; Voss, E.W., Jr. Partial elucidation of an anti-hapten repertoire in BALB/c mice: Comparative characterization of several monoclonal anti-fluorescyl antibodies. Mol. Immunol. 1981, 18, 889–898. [CrossRef]
39. Huang, L.; Johnson, L.S. CD3-binding molecules capable of binding to human and non-human CD3. US 2014/0099318 A1, 10 April 2014.
40. Chichili, G.R.; Huang, L.; Li, H.; Burke, S.; He, L.; Tang, Q.; Jin, L.; Gorlatov, S.; Ciccarone, V.; Chen, F., et al. A CD3ÖCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates. Sci. Transl. Med. 2015, 7, 1–13. [CrossRef][PubMed]
41. Finlay, W.J.; Bloom, L.; Cunningham, O. Optimized generation of high-affinity, high-specificity single-chain Fv antibodies from multiantigen immunized chickens. In Protein Chromatography: Methods and Protocols; Walls, D., Loughran, S.T., Eds.; Humana Press, Springer Science: New York, NY, USA, 2011; Volume 680, pp. 383–401.
42. Wasley, L.C.; Rehemtulla, A.; Bristol, A.; Kaufman, R.J. PACE/furin can process the vitamin K-dependent pro-factor IX precursor within the secretory pathway. J. Biol. Chem. 1993, 268, 8458–8465. [PubMed]